Novo Nordisk: Riding High on Diabetes

Novo Nordisk is confident that it can continue to generate strong growth from its leading diabetes franchise. Having exited oral anti-diabetics, it's betting on further innovation in insulin and on a strong entry into the GLP-1 analog space.

Melanie Senior

A few years ago, the talk at Novo Nordisk AS was of diversifying away from insulin and diabetes. Today,...

In Vivo Podcast

Candid conversations with C-suite leaders.

Keep up with strategy, innovation and evolving trends across life science industries.

More from Business Strategy

More from In Vivo